Matching slides 303,780
Current window 203,371-203,400
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

203,371-203,400 of 303,780

filter-aware
31
The slide uses topographical brain maps to visualize EEG data changes. Significant channels are marked with black circles.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
32
Slide 32 of a presentation.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
34
The slide uses a vertical process flow to show the progression from pre-clinical to clinical phases, mapped against key de-risking milestones.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
35
The slide uses a grouped bar chart to show T-scores across three cognitive tests (HVLT, Symbol Coding, Category Fluency) for four dosage groups.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
36
Includes study design diagram and assessment schedule table.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
38
The slide uses a chemical structure diagram to establish the scientific basis for the product.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
39
The slide outlines two distinct clinical study parts: a Single Ascending Dose (SAD) study and a crossover comparator study.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
40
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
41
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · Solution1 hit
01
Slide 1
Includes company logo, date, and corporate tagline.Athira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
02
Athira Pharma | Results Presentation Deck | 11 slidesAthira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
03
The slide uses a bulleted list to summarize clinical trial milestones and data-driven decision-making.Athira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
10
Athira Pharma | Results Presentation Deck | 11 slidesAthira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
11
The slide uses a grid of metrics to establish the market size and the problem (lack of new treatments).Athira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
01
Slide 1
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
02
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
03
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
04
The slide features a high-quality illustration of neurons, emphasizing the CNS focus of the company.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
05
The slide uses a simple additive equation visual to represent the growth of the company's CNS portfolio.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
06
The slide uses a Gantt-style visualization to track drug development progress.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
08
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Solution1 hit
09
Includes a scientific diagram of the GABAa receptor complex.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Solution1 hit
11
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
12
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
14
The slide uses a hexagonal layout to present five key product attributes.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Market SizeLoop · Cost Of Inaction1 hit
15
The slide notes that BAER-101 was previously known as AZD7325.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Product1 hit
17
Includes a comparison to Cerevel's darigabat and lorazepam.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
18
The chart shows BAER-101 regimens consistently resulting in lower sleepiness rates than Lorazepam.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
19
Includes a medical warning regarding photosensitivity.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
20
The slide uses a comparison table to frame BAER-101's selectivity profile as a competitive advantage.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit